6-K

Genenta Science S.p.A. (GNTA)

6-K 2024-12-13 For: 2024-12-13
View Original
Added on April 06, 2026

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM6-K

Reportof Foreign Private Issuer

Pursuantto Rule 13a-16 or 15d-16

Underthe Securities Exchange Act of 1934

Forthe month of December 2024

CommissionFile Number: 001-41115

GENENTASCIENCE S.P.A.

(Translationof Registrant’s Name into English)

ViaOlgettina No. 58

20132Milan, Italy

(Addressof principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

This report on Form 6-K is incorporated by reference into the registrant’s registration statement on Form F-3 (File No. 333-271901).


OtherEvents

AGCLetter of Intent Amendment

As previously reported in its Report on Form 6-K furnished on November 14, 2024, on October 31, 2024, Genenta Science S.p.A. (“Genenta”) entered into a letter of intent (the “LOI”) with AGC Biologics S.p.A. (“AGC”), pursuant to which Genenta and AGC agreed to negotiate the terms of a development and manufacturing services agreement for Genenta’s cell therapy products (the “Proposed Agreement”) and to execute the Proposed Agreement by December 15, 2024 (the “Negotiation End Date”). On December 11, 2024, the parties amended the LOI (the “LOI Amendment”) to extend the Negotiation End Date to December 20, 2024, resulting in a five-day extension.

The above description of the LOI Amendment is qualified in its entirety by reference to the LOI Amendment, a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

Exhibits

Exhibit No. Title
10.1 Letter of Intent Amendment, dated December 11, 2024, between AGC Biologics S.p.A. and Genenta Science S.r.l.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GENENTA<br> SCIENCE S.P.A.
Date:<br> December 13, 2024 By: /s/ Pierluigi Paracchi
Pierluigi<br> Paracchi, Chief Executive Officer

Exhibit 10.1